18 Aug 2007
A wide body of research has shown that classical forms of bacteria often transform into tiny variants of the same species, losing their cell walls in the process. They are then referred to as L-form or cell wall deficient (CWD) bacteria. Although researchers have known about L-form bacteria for over a century, up until recently they have not fully understood their connection to chronic disease. It is now known that these bacteria are responsible for causing a wide array of chronic diseases including rheumatoid arthritis, Chronic Fatigue Syndrome, Lyme disease, and sarcoidosis.
Over the past century researchers have identified over 50 different species of bacteria capable of transforming into the L-form and it is likely that even more species will be discovered in the coming years. The vast majority of researchers and doctors are not aware that L-form bacteria are present in their patients because the pathogens will not grow under standard laboratory conditions and must be cultured in a different medium and at a different temperature than classical bacteria.
In 2005, a team of researchers at the Royal Brompton Hospital in London published a paper that reviewed the clinical significance of the L-form as an infectious agent. The review discussed the work of hundreds of researchers who have cultivated the L-form and implicated it in a wide array of diseases.
This piece describes several of the doctors and researchers discussed in the review who have perfected the lab methods needed to correctly culture L-form bacteria and have consequently been able to observe and document their behavior. L-forms have also been studied extensively in veterinary literature but those findings are not presented here.
In 1895 a scientist named Richard Pfeiffer described an altered form of the bacteria Vibrio cholerae that was difficult to see with a light microscope. Other workers in his lab confirmed that the bacteria lacked cell walls and were difficult to grow using standard laboratory techniques.
Around the same time, Ernest Alnquist, a friend of Louis Pasteur, began to culture the L-form. Alnquist was the first to suggest how extensive and diverse L-forms are. He once commented that “nobody can pretend to know the complete life cycle and all the varieties of even a single bacterial species. It would be an assumption to think so.”
In 1941, German scientist Emmy Klieneberger-Nobel began to study the L form at the Lister Institute in England. A meticulous lab worker, Klieneberger-Nobel, perfected the method of growing the pathogens on serum (blood) agar.
After growing colonies of the bacterium Streptobacillus monliforme she confirmed that several of the pathogens in her Petri dish did indeed lack cell walls. She named the wall-less variants L-forms after the Lister Institute where she worked. In the years that followed she studied other species of L-forms and published several papers describing their characteristics and behavior. She once said that “the L-form is an entity of its own as different from bacteria as the tadpole from the frog.”
A few years later, Harvard Medical School researcher Louis Dienes began to work with the L-form. He applied penicillin to various species of classical bacteria such as Salmonella typhosacoule and discovered that some of the pathogens transformed into cell wall-less variants of the same species. They also found that exposing the original strains to other antibiotics in the same class as penicillin, chemical injury, high levels of amino acids, lithium, calcium, chromatin and mercuric salts could cause L-form variants to form as well.
In many of his experiments Dienes noted that the individual L-forms in his samples often swelled into large round bodies. He also found that small colonies of L-form bacteria such as S.moniliformis are able to revert back to the classical form. He published numerous papers detailing his discoveries and was one of the first scientists to warn the medical community that some antibiotics such as penicillin can actually precipitate the formation of L-form bacteria.
Dienes kept his lab open at all times so that anyone interested could see his L-form cultures and ask questions about how to grow them correctly. Nevertheless, few of the other researchers at Harvard took note of his work. He once remarked that he only became known to the medical staff after a hospital art show displayed some of his watercolors.
Around the same time, a team of doctors under Virginia Wuerthele-Caspe Livingston cultured L-form bacteria from patients with the skin disease scleroderma. Livingston noted that some of the L-forms she observed were as small as viruses. But others were the size of classical bacteria and some were larger forms resembling spores of fungi and yeasts
Livingston and her colleagues injected the L-form bacteria they collected from patients with scleroderma into chicks and guinea pigs. The chicks died. Some of the guinea pigs developed hardening of the skin like scleroderma, and some developed cancer. In the years that followed Livingston was also able to grow L-forms from various human cancer tumors.
Her work was published in the American Journal of Medical Sciences and in the years that followed she wrote several books on the subject.
In 1975, H.M Butler and team wrote a review of L-forms, describing their resistance to penicillin and ability to change form. They concluded that “such organisms may be clinically significant in cases of chronic and recurrent infection.”
At the same time, Bisset and Barlett identified L-form variants of Bacillus licheniformia during different stages of its life cycle. They hypothesized that the wall-less variants of the bacteria they observed had previously been wrongly classified as other species of pathogens.
A decade later, a doctor working at Columbia University by the name of Emil Wirostko began to culture and photograph L-form. In a series of related experiments, he took white blood cells from the liquid inside the eyes of patients with sarcoidosis, juvenile rheumatoid arthritis and Crohn’s disease and observed them under an electron microscope.
He detected L-forms in many of the specimens and noticed that the bacteria were grouped into colonies and encased inside tubuoles. He also noted that they were separated from the environment inside the cell by a membrane or exoskeleton that kept them from being digested by the cell.
Wirostko published three papers that detailed his findings and took many pictures of the L-forms he observed, 20 of which are dispersed throughout his papers.
Around the same time, researcher Alan Cantwell took great interest in Livingston’s work and proceeded to study the L-form. He applied a technique called acid fast staining to the tissue sections of the skin and lymph nodes of patients with the lung disease sarcoidosis and found L-forms in his samples. Cantwell later isolated the L-form of Streptococcus B from the lymph nodes and blood of patients with HIV. He noted that the L-forms he observed could grow into extremely large forms and determined that they were what are known as “Russell bodies.”
In the years that followed, Cantwell took samples from the lymph nodes, skin tumors and other organs from the corpses of patients who had died from Hodgkin’s disease and cancer. He found copious amounts of L-form bacteria in his samples, including round forms resembling the bacterial species staphylococci and rod-shaped bacteria known as corynebacteria.
Over the course of his career Cantwell published over 30 papers and wrote several books that implicate the L-forms in chronic disease, including a book about Livingston and three other women who had worked on her research team.
Around the same time, researcher Lida Mattman began to study the L-form. After working as senior bacteriologist at the University of Massachusetts, she became the director of a laboratory that evaluated specimens sent by mail from doctors around the world. Mattman, who would study and photograph the L-from over the course of decades, confirmed that the pathogens could vary widely in size and shape.
Mattman’s success in growing L-forms was due in part to a relentless drive to perfect the laboratory techniques which allowed her to culture the pathogens. She used fluorescent antibodies and a variety of staining techniques to view the various cell wall deficient forms. She even figured out how to grow them directly on slides.
Mattman studied patients with Tuberculosis and found that in every patient tested, the blood was saturated with a variety of L-forms.
She identified two different species of L-form bacteria in patients with Parkinson’s Disease. The L- form species of Borrellia burgdoferi was detected in patients with Lyme disease. She cultured serum from forty patients with multiple sclerosis and found a different species of the borrelia L-form present in her samples. Soon after, she detected Chlamydia pneumonia in the blood of patients who had suffered a pulmonary thrombosis. She also found bacteria that resembled M. tuberculosis in the blood of patients with the lung disease sarcoidosis.
In the end, Mattman detected dozens of species of L-form bacteria and was able to culture these wall-less forms of bacteria from the blood samples of patients with over 20 incurable illnesses. She published numerous papers throughout her career and in authored an entire medical textbook in which she details her findings.
In 1997 a team of researchers at Tulane University under Gerald Domingue published an extensive review article on chronic bacterial infection in Clinical Microbiological Reviews. Among their conclusions was the claim that ”the difficult to culture and dormant bacteria are involved in latency of infection and that these persistent bacteria may be pathogenic.”
The review also detailed how L-form bacteria are able to form electron dense bodies within previously infected cells. Domingue implicated L-form bacteria in several kidney-related diseases including pyelonephritis, glomerulonephritis, idiopathic hematuria, and Interstitial cystitis. He also speculated about their role in other diseases such as rheumatic fever, tuberculosis, syphilis, and rheumatoid arthritis.
In the review Domingue states “Certainly, any patient with a history of recurrent infection and persistant disability is sending the signal that the phenomenon (infection with L-form bacteria) is occurring. The so called autoimmune diseases in which no organism can be identified by routine testing techniques are particularly suspect.”
Over the course of his thirty-nine year career Domingue published 65 papers, monographs, and book chapters about L-form bacteria. He was invited to deliver over fifty international and national lectures about atypical forms of bacteria and wrote a book on the subject called Cell Wall-Deficient Bacteria: Basic Principles and Clinical Significance.
Several years later, Kenneth Nilsson, a researcher at Uppsala University Hospital in Sweden, published photos of the bacteria Rickettsia helvetica living inside the white blood cells of patients with sarcoidosis. The fact that the bacteria was able to persist inside the cells suggested that something was very wrong with the patient’s immune systems. Dozens of other researchers have also implicated other species of L-forms in sarcoidosis.
A decade later, researchers at the Academy of Science in Bulgaria infected rats with the L-form of Staphylococcus aureus and found that the pathogen were able to “internalize, replicate and persist “ in the lungs of the infected rats. They concluded that “cell wall deficient bacterial forms may be involved in the pathogenesis of chronic and latent lung infections.”
A team of researchers and doctors in the United Kingdom are currently studying the L-form in patients with Chronic Fatigue Syndrome (CFS). The microbiology team, lead by CFS clinician Dr. Andy Wright has detected L-forms in every single one of the CFS patients they have tested (about 600 to date).
Wright has developed a method of taking pinprick blood (usually from the ear) and allowing it to degrade for 6-36 hours. The process causes the L-form bacteria to break out of the cells and they can subsequently be observed with a dark field microscope. The bacteria can be stained with fluorescent dye. If the L-forms are alive they will stain green, while dying/dead L-forms stain orange. Wright has created several videos of L-forms under the microscope in which the pathogens can be seen quite clearly.
In the videos, the bacteria often lengthen into long filamental forms that look thin and snakelike. They can be seen weaving in between infected cells. Sometimes “giant” L-forms, which are more rectangular in shape, begin to grow inside the cells.
Danish researcher Marie Kroun has also taken several videos of L-form bacteria under a high-resolution microscope.
However it’s quite possible that L-form bacteria might have remained in relative obscurity if a scientist from Adelaide Australia by the name of Trevor Marshall hadn’t taken an interest in their ability to persist in the body. Marshall wasn’t a medical doctor – he was an biomedical engineer with an impressive grasp of molecular modeling software. Whereas a doctor can look at a patient and infer a mechanism for disease based only on symptom presentation, a biomedical researcher can take the actual compounds created by L-form bacteria and mathematically determine how they affect the body’s receptors and enzymes.
Thus, after decades of research, Marshall was able to succeed in two areas where the L-form researchers before him had failed. By combining precise molecular modeling data with previous research on stealth bacteria, he was able to create a model that explained exactly how L-form bacteria are able to dysregulate the immune system and persist in the body. Secondly, he was able to use his model in order to create a treatment that effectively kills L-form bacteria. The Marshall Protocol was born. Patients on the treatment use pulsed, low-dose antibiotics, along with a medication that activates the immune system to eliminate L-form bacteria over a period of several years.
Patients with a wide array of chronic diseases are using the treatment. Most are reporting symptomatic improvement and a number of patients have claimed complete resolution of symptoms.
Marshall has since written several papers and given numerous presentations that detail the pathogenesis of chronic disease.
Almenoff, P.L., Johnson, A., Lesser, M., & Mattman, L.H. (1996). Growth of acid fast L forms from the blood of patients with sarcoidosis. Thorax, 51(5), 530-3.
Bissett, K.A. & Barlett, R. (1978). The isolation and characters of L-forms and reversions of Bacillus licheniformis var endoparasiticus (Benedek) associated with the erythrocytes of clinically normal persons. J Med Microbiol, 11: 335-349.
Butler, H.M., & Blakey, J.L. (1975). A review of bacteria in L-phase and their possible clinical significance. The Medical journal of Australia, 2(12), 463-7.
Cantwell, A.R. Virginia Livingston – Cancer Quack Or Medical Genius? Retrieved August 16, 2007.
Cantwell, A.R. (1982). Histologic observations of variably acid-fast pleomorphic bacteria in systemic sarcoidosis: a report of 3 cases. Growth, 46(2), 113-25.
Cantwell, A.R. (2006). Bacterial Infection as the Cause of Scleroderma. Journal Of Independent Medical Research.
Cantwell, A.R. Pleomorphic Bacteria as a Cause of Hodgkin’s Disease (Hodgkin’s lymphoma). Journal Of Independent Medical Research.
Domingue, Sr , G., & Woody, H. (1997). Bacterial persistence and expression of disease. Clin Microbiol Rev, 10(2), 320-344.
Holmes, K.K., Gutman, L.T., Belding, M.E., & Turck, M. (1971). Recovery of Neisseria gonorrhoeae from “Sterile” synovial fluid in gonococcal arthritis. The New England journal of medicine, 284(6), 318-20.
Klieneberger-Nobel, E. (1951). Filterable forms of bacteria. Bacteriol Rev, 15(2), 77-103.
Marshall, T., Fenter, B., & Marshall, F. Antibacterial Therapy Induces Remission in Sarcoidosis. Journal Of Independent Medical Research.
Mattman, L.H. (2000). Cell Wall Deficient Forms: Stealth Pathogens. CRC Press.
Merline, J.R., Golden, A., & Mattman, L.H. (1971). Cell wall deficient bacterial variants from man in experimental cardiopathy. American journal of clinical pathology, 55(2), 212-20.
Onwuamaegbu, M., Belcher, R., & Soare, C. Cell Wall-deficient Bacteria as a Cause of Infections: a Review of the Clinical Significance. J Int Med Res, 33(1), 1-20.
Phillips, S.E., Mattman, L.H., Hulínská, D., & Moayad, H. A proposal for the reliable culture of Borrelia burgdorferi from patients with chronic Lyme disease, even from those previously aggressively treated. Infection, 26(6), 364-7.
11 Responses for "A History of Cell Wall Deficient Bacteria: A Selection of Researchers Who Have Worked with the L-form"
The article written by Ms. Amy Proal on cell wall-deficient bacteria was brought to my attention by a colleague. I retired from active research/academia ten years ago; however,I continue to have an interest
in the literature on bacterial persistence and expression of disease. A large part of my scientific career (30 years) was devoted to a study of the basic biology of cell wall-defective bacteria,cell wall-deficient bacteria, L-forms, Large Bodies, Cryptic bacteria (or whatever you wish to name them) and their possible role in disease. Since retirement, I have refrained from commenting on any type of publication in the field; however, I thought it might be worthwhile and helpful to Ms. Proal and to those who do not know the literature or deliberately choose to ignore it, to call attention to the following peer reviewed publications. It is disappointing to see nowadays that many researchers/writers fail to appropriately cite relevant references from the past scientific and medical literature. This all falls in what I call the “ethics of scientific writing” which too often is violated. Sometimes ridiculously tumid claims are made in papers; many unsubstantiated by scientific data or evidence.
Following are selected relevant references from the peer reviewed scientific literature (as well as a book) on atypical or cryptic bacterial studies emanating from my laboratory over several decades which may be useful to consider:
l. Journal of Urology. 104:790-798, 1970.
2. Investigative Urology. 9:282:285, 1972.
3. Proceed. of Soc. for Exptl. Biol. and Med. 146:635-642, 1974.
4. Infection and Immunity. 10:889-914, 1974.
5. Infection and Immunity. 10:915-917, 1974.
6. Microbia. 1:3, 1976.
7. Infection and Immunity. 15:621-627, 1977.
8. Journal of Urology. 120:708-711, 1978.
9. Trans. Am. Assoc. Genito-Urinary Surg. 69:61-64, 1978,
10. Archives of Internal Medicine. 139:1355-1360, 1979.
11. Urol. Survey. 30:1-4, 1980.
12. J. Urol. 150:483-485, 1993.
13. J. Urology. 153:1321-1326, 1995.
14. Endocytobiosis and Cell Research, 11:19-40, 1995.
Book:
Domingue, G.J., Editor, Cell Wall-Deficient Bacteria: Basic Principles and Clinical Significance, Addison-Wesley Publishing Co., Reading, MA, 1982.
Gerald J. Domingue
Zurich, Switzerland
Professor Emeritus
Tulane University School of Medicine and Graduate School
New Orleans, Louisiana
“She cultured serum from forty patients with multiple sclerosis and found a different species of the borrelia L-form present in her samples.”
I guess my question is: Has anyone tried to treat this strain of borrelia in an actual MS patient to see if it has any effect on their condition?
This is the best bacterial site I have seen on the net. I applaud your effert and really appreciate the work you have done.
Hi D Bergy,
I’m glad you find this site to be informative and thanks for your nice comments about my work!
The MP is the only treatment that effectively kills L-form bacteria, so the only way people with MS could target Borrelia L-forms would be through the MP. However since the MP kills different species of L-form bacteria simultaneously, it would be impossible to do a study in which only Borrelia L-forms were being killed.
Unfortunately high dose and IV antibiotics do not effectively kill L-form bacteria, because as described in this article, at such high doses, they negatively affect the immune system:
“Getting it Right: How to correctly target L-form bacteria”
http://bacteriality.com/2007/10/11/antibiotics/
The good news is that there are an increasing number of MS patients on the MP who appear to be recovering in the same fashion as people with other Th1 diseases. They are definitely experiencing immunopathology – a clear indication that L-form bacteria are being targeted.
Best,
Amy
this is very nice
If this leads to a blood test for me/cfs then I’m all for it! So nice to read something medical that a lay person can understand for a change! kudos on the site, it’s a marvel.
This is very useful for my final exam.Thank you
Hi Syed,
Glad to be of help and glad you are writing about L-forms!
Best,
Amy
Hello,
First of all, I would like to applaud Amy on this article. It is very insightful. Secondly, I have a question for Amy or Gerald. I am only a sophmore working on a Bioengineering degree so I apologize if the question is completely stupid. Do these L-form bacteria retain the protein receptors or other various surface proteins that they have on the extracellular side of the plasma membrane that they have in their “normal” form? If so, what type of molecules bind to these sites? Thanks for your help!
Hi Zac,
I’m glad you are interested in learning more about L-form bacteria. I have forwarded your questions to Dr. Domingue as his answer should be more complete than mine. I’ll email you if he gets back to me.
Take care,
Amy
Since last May (2008) I have been treating these L-forms electrically according to Hilda Clark from her book, “One Cure for all Diseases”. I put patients on the “Zapper”—for lack of a better term, one time evdry two weeks. In the interim I send My patients home with an essential oil blend that stops the function of these bacteria by interupting their reproductive cycle.
We then re-test in two weeks, “zapp” and adjust the number of drops of the oil necessary to continue the healing process. Patient results have been excellent, more energy, mental clarity, better stamina. The list goes on and on.
Dr. Quell
Hi Dr. Quell,
Thanks for sharing. I personally have never heard of using the zapper to treat any inflammatory condition. Also, when you blend of oils, do they contain any omega 3? If so, they contain vitamin D and could simply be suppressing the innate immune response against L-form bacteria. My major question about the way you treat your patients is – do they experience a powerful bacterial die-off reaction when administered the zapper and oils? Since it is now known that L-form bacteria cannot be killed without generating an inflammatory response that leads to temporary rises in disease symptoms, do your patients deal with such symptom exacerbation?
If not, I feel you may not be targeting L-forms completely. I’m just trying to be honest here, I don’t mean to insult your work. On the contrary, I applaud you for considering that L-form bacteria could be making your patients ill.
Have you read about the Marshall Protocol? It’s the study/treatment described often on this site that was also created about six years ago to target L-from bacteria. I’m not trying to market it to you since it’s run by a non-profit agency and the guidelines and services are all completely free. I just feel that you might be interested in learning more about it since obviously you care deeply about your patients’ health and are interested in L-forms.
The following video describes the treatment and the science that forms its backbone in simple terms:
http://bacteriality.com/2008/05/07/mpintro/
Here’s a quick summary of the MP:
http://bacteriality.com/about-the-mp/
Here’s a link to Dr. Marshall’s (head of the Foundation) published papers and conference speeches:
http://mpkb.mp-dev.com/doku.php/home:publications
Thanks for writing,
Amy
Leave a reply
Please be aware that comments or questions about the Marshall Protocol tend to be answered much more quickly at CureMyTh1.org.